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Abstract The impact of improved treatments for the
management of hormone-sensitive breast cancer extends
beyond clinical responses. Thanks to appropriate literature
and access to the internet, patient awareness of treatment
options has grown and patients are now, in many cases, able
to engage their oncologists in informed conversations
regarding treatment and what to expect in terms of efﬁcacy
and safety. Indeed, patients realize that although there is no
cure for metastatic disease, treatment can greatly reduce the
risk of progression and in the adjuvant setting, where treat-
ment is administered with a curative intent, current treatment
options reduce the risk of relapse. The approval of letrozole
throughoutthebreastcancercontinuumhasprovidedpatients
with many reassuring options. The improvement in outcome
with letrozole is achieved without a detrimental effect on
overall quality of life. Adverse events such as hot ﬂushes,
arthralgia, vaginal dryness, and potential osteoporosis are
most signiﬁcant from the patient’s perspective, and it is
important that caregivers pay attention to patients experi-
encing these events, as they can impact compliance unless
effectively explained and managed. The major beneﬁts of
letrozole are to improve prospects for long-term survivorship
in the adjuvant setting and to delay progression and the need
for chemotherapy in the metastatic setting.
Keywords Adjuvant therapy  Aromatase inhibitors 
Breast cancer  Letrozole  Neoadjuvant therapy  Patient
Introduction
The diagnosis of breast cancer is a devastating blow for
women and is associated with depression, anxiety, and a
range of other psychological problems, such as self-blame
and negative perception of body-image [1–5]. Newly
diagnosed metastatic breast cancer (MBC) is also associ-
ated with high levels of psychological morbidity,
particularly for younger women [6]. Prevention of relapse
is a long-term therapeutic imperative, but the impact of
therapy on quality of life (QOL) also needs to be taken into
consideration when planning treatment strategies.
All therapeutic modalities for early breast cancer
(mastectomy or lumpectomy, radiation, chemotherapy,
antibody therapy and endocrine therapy) can have a sig-
niﬁcant impact on patients’ QOL both in the short-term and
in the transition period from primary treatment to long-
term survivorship [7–9]. Receiving good quality informa-
tion about prognosis, treatment options, side effects, and
risks of breast cancer recurrence is, therefore, important for
patients diagnosed with breast cancer [10–13].
The third-generation aromatase inhibitor (AI) letrozole
was introduced a decade ago, but at that time, a limited
amount of information on breast cancer and its treatment
was available to patients. Since then, the international
oncology community has made major advances in its
knowledge about breast cancer biology, the individualiza-
tion of treatment options, and communication with
patients. Greater understanding of genetics and breast
cancer risk has improved approaches for counseling indi-
viduals about their susceptibility [14]. In women who
N. Harbeck (&)  R. Haidinger
Frauenklinik der Technischen Universita ¨tM u ¨nchen,
Ismaninger Strasse 22, Mu ¨nich 81675, Germany
e-mail: nadia.harbeck@lrz.tum.de
R. Haidinger
Brustkrebs Deutschland e.V., Charles-de-Gaulle-Str. 6,
Mu ¨nich 81737, Germany
e-mail: renate.haidinger@web.de
123
Breast Cancer Res Treat (2007) 105:91–103
DOI 10.1007/s10549-007-9703-8develop breast cancer, the individualization of treatment is
becoming more sophisticated through the use of biomark-
ers as prognostic and predictive factors. These include
human epidermal growth factor receptor (HER) 2 [15, 16],
urokinase-type plasminogen activator and plasminogen
activator inhibitor type 1 [17, 18], mRNA expression pat-
terns [19, 20], and, more recently, genetic proﬁling
techniques [21, 22]. Individualizing treatment is also made
easier by the ability to more accurately determine the
patient’s risk factors and prognosis; for example, by using
the Adjuvant! Online program [23–25]. Recognizing breast
cancer overtreatment has also contributed to tailoring
treatment according to individual risk [26–30]. Oncology
teams have facilitated patient involvement in selecting the
most appropriate therapy [24, 31, 32] and have improved
the provision of patient information, support, and coun-
seling [33, 34].
At the same time, patients began to organize effectively
and expand their access to knowledge of new drugs and
treatment paradigms [35–37]. Patients have learned to be
informed so that they can have constructive dialogues with
their doctors and feel they understand and contribute to
treatment decisions [38–42]. Patients who take an active
role in the decision-making process perceive that they have
a treatment choice, in contrast to those who prefer a shared
or passive role [43]. They know they cannot be told at any
time during the course of their disease that they are or are
not cured; they recognize that breast cancer is a chronic
illness. Patients are now empowered with hope and the
knowledge that breast cancer can be managed. Moreover,
increased survival rates have prompted greater interest in
the QOL of breast cancer survivors [44–46].
Better education and improved access to screening has
resulted in fewer patients being diagnosed with advanced
breast cancer at their ﬁrst presentation, and consequently,
mortality has decreased [29, 47–49]. In addition, more
effective adjuvant therapy with third-generation AIs has
signiﬁcantly decreased the risk of recurrence as compared
with the previous standard of care based on tamoxifen [50–
53]. However, there remains a long-term risk of breast
cancer recurrence over time [54, 55]. Hormone receptor-
positive (HR+) breast cancer is particularly challenging
because of the persistent risk of recurrence with this
chronic ‘‘smoldering’’ disease. The Early Breast Cancer
Trialists Collaborative Group meta-analysis showed that in
untreated women with the same nodal status, the breast
cancer death rate is greater for patients with estrogen
receptor-negative (ER–) versus ER+ tumors in the ﬁrst 5–
6 years, but substantially lower for ER– versus ER+ tumors
over the next 10 years [56]. Similarly, Saphner reported
that beyond 5 years, the risk of recurrence was higher for
patients with HR+ tumors than for those with HR– tumors
(P = 0.00002) [54].
Patients may experience stress after medical therapy is
ended because they feel they have lost a safety net [57, 58].
This fear is understandable and justiﬁable in view of
the persistent risk of recurrence for HR+ breast cancer.
An analysis of the MA.17 trial of extended adjuvant ther-
apy recently showed an increasing risk of disease
recurrence over time in patients treated with placebo after
discontinuing tamoxifen [59]. Not surprisingly, therefore,
patients may be willing to receive long-term therapy
(extended adjuvant) to prevent recurrence provided that the
beneﬁts outweigh the risks and QOL is maintained [60].
Patients will try to tolerate treatment-related adverse events
if there is the prospect of achieving a ‘‘cure,’’ i.e. remaining
free of relapse during their lifetime.
Tamoxifen was the mainstay of breast cancer therapy,
but its time-dependent efﬁcacy and serious adverse events
created a need for new therapies [61–63]. The suppression
of estrogen was shown to be greater and more selective
with third-generation AIs than with ﬁrst- and second-gen-
eration compounds [64], and this has resulted in better
clinical outcomes and improved tolerability [65]. This
review examines the clinical use of the third-generation AI
letrozole from the patient’s perspective and assesses how it
has improved treatment outcomes across the breast cancer
continuum, including advanced or MBC, extended and
initial adjuvant therapy, and neoadjuvant therapy.
Metastatic setting
Endocrine therapy is the ﬁrst-choice treatment for women
with HR+ breast cancer without acute life-threatening
symptoms and should be administered for as long as possible
before switching to cytotoxic regimens. Endocrine therapy is
preferred to cytotoxic chemotherapy because of its more
favorable safety proﬁle [66]. Thus, extending the time to the
initiation of chemotherapy is important with endocrine
therapy, because a considerable proportion of patients who
progress to chemotherapy will experience toxic side effects
without gaining beneﬁt [67]. The most common acute side
effects of chemotherapy, such as leukopenia, alopecia, and
nausea and vomiting, are signiﬁcantly increased in women
receivingcombinationregimenscomparedwithsingle agents
[68]. Chemotherapy can also adversely affect certain aspects
of QOL, notably increasing fatigue [69], and some regimens
may be associated with severe or life-threatening complica-
tions such as cardiac failure [70]. A meta-analysis to review
the evidence and determine whether chemotherapy or endo-
crine therapy has the most beneﬁcial effect on treatment
outcomes (survival, response rate, toxicity, and QOL) con-
cluded that in women with HR+ MBC, a policy of treating
ﬁrst with endocrine therapy rather than chemotherapy is
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disease [71].
Prior to the introduction of third-generation AIs, post-
menopausal patients with hormone-responsive MBC had
few endocrine therapy options other than tamoxifen [62].
Second-line endocrine agents were limited by safety con-
cerns, including weight gain or the risk of thromboembo-
lism with megestrol acetate [72, 73] and cardiovascular
toxicity with aminoglutethimide [65]. Randomized con-
trolled trials demonstrated that letrozole is better tolerated
and more effective than these second-line endocrine agents
[65, 72, 73]. Furthermore, letrozole has also demonstrated
superior early survival compared with tamoxifen as ﬁrst-
line therapy in postmenopausal patients with MBC [74].
Importantly, longer time to disease progression with
letrozole versus tamoxifen was achieved without increased
time with adverse events and resulted in more quality-
adjusted survival for patients on letrozole [75]. Maintaining
functional ability is an important goal for patients treated in
this setting. A subanalysis by different sites of metastatic
lesion and Karnofsky Performance Scores also showed the
superiority of letrozole compared with tamoxifen in
patients with nonvisceral metastases, with visceral metas-
tases without liver involvement, and with liver metastases
[76]. From the patient’s perspective, it is important to
receive the most effective therapy ﬁrst-line; therefore,
letrozole represents a more attractive option than tamoxifen
for postmenopausal women.
Pharmacologic and clinical differences exist between
third-generation inhibitors and should be considered in the
selection of the most appropriate endocrine therapy [64,
77]. Data from a small randomized crossover trial in 72
postmenopausal women with HR+ MBC showed that
overall QOL was signiﬁcantly better with letrozole than
with anastrozole (P = 0.002 for mean total Functional
Assessment of Cancer Treatment-endocrine symptoms)
[78]. Furthermore, letrozole was signiﬁcantly better toler-
ated overall than anastrozole. Less nausea, fewer hot
ﬂashes, and less abdominal discomfort resulted in almost
twice as many patients preferring letrozole to anastrozole
[78].
While letrozole is an appropriate ﬁrst-line therapy for
the majority of patients with hormone-responsive MBC, a
small subset of patients with HR+ HER2+ tumors have
high-risk disease and are candidates for early treatment
with chemotherapy plus the anti-HER2 monoclonal anti-
body trastuzumab [79]. A meta-analysis of 12 studies
involving 2,379 patients with MBC demonstrated that
HER2+ tumors are less responsive than HER2– tumors to
endocrine treatment (overall relative risk 1.42; 95% con-
ﬁdence interval, 1.32–1.52; P\0.00001) [80]. Evidence
from preclinical models suggests that trastuzumab may
overcome relative resistance to endocrine therapy [81],
providing the rationale for combining anti-HER2 and
endocrine therapies in the clinical setting. Recently, the
ﬁrst published results of an AI in combination with an anti-
HER2 antibody (i.e. trastuzumab) show that the combina-
tion demonstrated durable responses for at least 1 year in
25% of patients [82]. Preliminary results from a phase 3
trial (TrAstuzumab in Dual HER2 ER-positive Metastatic
breast cancer) demonstrated that the combination of trast-
uzumab with an AI (anastrozole) was more effective than
anastrozole alone in postmenopausal patients with HR+
HER2+ MBC [83]. Another phase 3 trial, which is
enrolling more than 1,200 patients in this setting and has
just ﬁnished recruitment, is investigating letrozole in
combination with lapatinib, a dual inhibitor of HER2 and
HER1 tyrosine kinases [84]. The strategy of combining
letrozole with trastuzumab (as investigated in the evalua-
tion of Letrozole combined with Trastuzumab trial), or
another HER2-directed therapy, may allow patients with
HR+, HER2+ tumors to safely delay the initiation of
cytotoxic chemotherapy.
Adjuvant therapy
Patients receiving adjuvant therapy expect their treatment
to prevent breast cancer recurrence and offer the prospect
of cure. However, even modest gains in survival are suf-
ﬁcient to make adjuvant endocrine treatment worthwhile
for premenopausal women with early-stage breast cancer
[85]. This beneﬁt threshold also appears to apply to women
with a higher risk of recurrence for whom adjuvant che-
motherapy is indicated [86]. Adjuvant therapy should be
tailored to suit the needs of individual patients based on
their clinical risk factors, attitudes, and personal life cir-
cumstances [25]. However, it is important to recognize that
individual preferences cannot always be fully explained on
the basis of treatment-related determinants and patient or
clinical characteristics [87].
The Anastrozole versus Letrozole: Investigation into
Quality of Life study compared the effects of anastrozole
and letrozole on estrogen levels, QOL, lipids, and bone
health [88]. A total of 185 postmenopausal women with
invasive breast cancer were randomized to receive adjuvant
therapy with either 12 weeks of letrozole followed by
12 weeks of anastrozole or vice versa. Of the patients who
have completed the 12 weeks of treatment (n = 146), 50
(34%) had a preference for neither drug, 50 (34%) pre-
ferred anastrozole, and 46 (32%) preferred letrozole.
Both estradiol (E2) and estrone sulfate levels (E1S) were
signiﬁcantly lower on letrozole than on anastrozole
(P\0.000001). Thus, 2.5 mg of letrozole reduces circu-
lating E2 and E1S levels to a signiﬁcantly greater degree
than 1 mg of anastrozole, with no signiﬁcant difference in
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levels might translate into improved clinical efﬁcacy,
although further studies, such as the ongoing Femara
Anastrozole Clinical Evaluation trial, are required to con-
ﬁrm these ﬁndings.
Patients with HR+ tumors need to consider the prospect
of life-long adjuvant therapy in view of the persistent risk
of disease recurrence [54, 56, 89]. Following the intro-
duction of third-generation AIs, there is much greater
choice in endocrine therapy. The challenge for physicians
is to select the most appropriate strategy to suit individual
patient circumstances. Letrozole ﬁrst entered the adjuvant
setting as a treatment option for patients completing
5 years of tamoxifen [90] and has demonstrated clinical
superiority over tamoxifen as initial adjuvant therapy [51]
and neoadjuvant therapy [91].
Neoadjuvant therapy
Neoadjuvant endocrine therapy with letrozole is an
attractive option for some postmenopausal patients with
HR+ early breast cancer [92], including elderly patients
who are unable or unwilling to undergo chemotherapy or
surgery, and patients with locally advanced HR+ tumors
who wish to have breast-conserving surgery but are not
suited for preoperative chemotherapy [91, 93]. In a ran-
domized controlled trial, letrozole demonstrated a superior
overall objective response rate and rate of breast-conserving
surgery compared with tamoxifen as neoadjuvant therapy
[91]. Currently, letrozole is the only AI approved in the
neoadjuvant setting (in the United Kingdom and 16 other
countries worldwide). It provides a reasonable therapeutic
alternative to preoperative chemotherapy in postmenopausal
women with HR+ disease in clinical situations where the low
toxicity of the regimen is considered an advantage, e.g. in
women older than 70 years [91]. However, patients need to
be aware that a longer course of therapy may be required
to achieve an objective response than is the case with
neoadjuvant chemotherapy [94]. In one study, neoadjuvant
letrozolewassafelygivenover12 monthstopostmenopausal
women with large operable or locally advanced HR+ breast
cancers [94]. A longer treatment course may suit some
patientsandgivethemmoretimetoconsidertheiroptionsfor
surgery, radiotherapy, and chemotherapy.
Neoadjuvant therapy with letrozole could be considered
a sensitivity test of endocrine therapy that might be
incorporated into strategies to individualize adjuvant
treatment according to response [95]. This would provide
reassurance to patients that they will be receiving an
adjuvant endocrine therapy that has shown activity against
their tumor. Objective assessment of the antitumor activity
of neoadjuvant letrozole can be made on the basis of
response rate and by analysis of predictive biomarkers. In
one study, neoadjuvant letrozole was found to inhibit tumor
proliferation (determined by the biomarker Ki67) more
effectively than tamoxifen [95]. Letrozole was effective
independently of HER2 expression status, although the
greatest difference between letrozole and tamoxifen was
seen in tumors that were HR+ and HER1/2+. Recent
evidence has suggested that HER2+ tumors can continue to
proliferate despite neoadjuvant letrozole or tamoxifen
treatment, which could imply therapeutic resistance that
may manifest later in the clinical course of the disease [96].
Biomarker studies may also reveal differences between
AIs. In a randomized comparative trial, letrozole and
anastrozole signiﬁcantly reduced proliferation in HR+,
HER2+ or HER2– tumors [97]. Decreased proliferation
was seen at all Allred ER expression levels with both
agents, but only letrozole showed a signiﬁcant effect in the
lower ER cases. In addition, more cases showed a reduc-
tion in progesterone receptor (PgR) expression following
letrozole than anastrozole [97]. Another study showed
evidence of a decrease in HER2 expression after neoad-
juvant treatment with letrozole [98].
Although complex, biomarkers may become increas-
ingly important from a patient’s perspective, because they
can help to improve the individualization of treatment.
Furthermore, biomarkers may be useful to predict the risk
of resistance to endocrine therapy and the need to consider
alternative approaches in the future, such as combination
therapies or cytotoxic chemotherapy. Knowing what to
expect next is important for patients. However, further
work is necessary to validate the use of clinical markers
and biomarkers in the neoadjuvant setting as surrogate end
points for long-term outcomes [96].
Early adjuvant therapy
Tamoxifen was the gold standard endocrine therapy for all
women with HR+ breast cancer until recent results from
large randomized trials challenged this paradigm for post-
menopausal women [50, 51, 99]. Oncologists and patients
now face an important choice when selecting adjuvant
endocrine treatment [66, 100], whether to start with the
most potent endocrine therapy (an AI) upfront or to start
with tamoxifen and switch to an AI inhibitor after
2–5 years. The ongoing Breast International Group (BIG)
1-98 randomized trial is expected to provide more infor-
mation on the beneﬁts of switching to letrozole after
2–3 years on tamoxifen and will clarify which is the
optimal strategy. The ﬁnal results are expected to be
released in 2008 [51], but until then, the most appropriate
endocrine therapy will need to be selected on the basis of
currently available evidence. The MA.17 trial has already
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5 years of adjuvant tamoxifen [90, 101, 102].
Patients will ideally wish to receive treatment that
provides the greatest long-term efﬁcacy with the lowest
risk of adverse events. BIG 1-98 showed that letrozole was
signiﬁcantly more effective than tamoxifen as initial
adjuvant endocrine therapy [51]. Moreover, tamoxifen is
perceived to be more toxic than AIs, largely because of
well-publicized ‘‘scares’’ about increased risk of uterine
cancer and thrombosis [61, 103]. These side effects and
vaginal bleeding were reported for tamoxifen in BIG 1-98,
whereas letrozole was associated with more skeletal events.
The overall rate of cardiovascular events was not signiﬁ-
cantly different between the groups. Letrozole was also
shown to be extremely well-tolerated in comparison with
placebo in the MA.17 trial [90, 101]. With the exception of
adverse events related to suppression of estrogen, there was
no difference in adverse events (Table 1).
Based on the results from the BIG 1-98 and the Anas-
trozole and Tamoxifen Alone or in Combination (ATAC)
trial, which compared upfront AIs with tamoxifen, it is
clear that all postmenopausal women with HR+ breast
cancer should be given the opportunity to receive adjuvant
use of an AI, and this recommendation is now reﬂected in
internationally recognized treatment guidelines [66, 100,
104, 105]. Patients with HR+ breast cancer considered
eligible for adjuvant chemotherapy because of their
increased risk for relapse should also be candidates for the
most effective adjuvant endocrine strategy [100]. Of note,
the BIG 1-98 trial showed that adjuvant letrozole provides
signiﬁcant disease-free survival (DFS) beneﬁts for patients
at increased risk of recurrence, speciﬁcally patients with
node-positive tumors, large primary tumors ([2 cm),
and recipients of chemotherapy and also demonstrated a
signiﬁcant reduction in the risk of distant recurrence, a
well-known predictor of breast cancer death [51]. Addi-
tional analyses of data from BIG 1-98 to determine the
predictive value of centrally tested ER, PgR, and HER2
status on the response to letrozole and tamoxifen indicate
that there is no difference in subgroups by ER/PR or HER2
status regarding the superiority of upfront letrozole versus
tamoxifen [106]. Low-risk patients with HR+ breast cancer
who do not receive adjuvant chemotherapy are also can-
didates for AIs [104] because of the persistent risk of
relapse [54, 56].
While it is known that tamoxifen loses effectiveness
after 5 years [62, 63], the optimal duration of initial
therapy with an AI remains to be determined [107]. The
MA.17 randomized controlled trial of extended adjuvant
endocrine therapy has already shown that letrozole treat-
ment is beneﬁcial after 5 years of tamoxifen in
postmenopausal patients [90, 101], but there are no
equivalent data on the use of tamoxifen after initial AI
therapy in the adjuvant setting [100]. Furthermore, the
efﬁcacy of switching to another AI in patients who dis-
continue treatment with letrozole is not known. Therefore,
patients starting upfront therapy with letrozole will need
reassurance that according to present knowledge, treatment
can be continued for up to 5 years, and other options will
be available down the line. In addition, patients will require
information about the potential long-term impact of AIs on
bone and the cardiovascular system [107].
According to the current treatment guidelines [66, 100,
104, 105], patients already taking a course of adjuvant
tamoxifen may wish to switch to anastrozole or exemes-
tane, as these AIs have demonstrated efﬁcacy in this
setting [52, 108, 109]. Although recent data have shown
that this sequential adjuvant strategy is associated with a
survival advantage [53, 110, 111], it is important to note
that these data were obtained from a selected population
comprising patients at randomization who were disease-
free after 2–3 years of tamoxifen. It is therefore not valid
to make a direct comparison with an unselected popula-
tion treated in trials of upfront AI therapy. The decision
to switch endocrine therapy after 2–3 years, i.e. for a
sequential tamoxifen–AI strategy, should be based on an
individual’s risk for recurrence, risk for osteoporosis, and
ability to tolerate tamoxifen. Importantly, BIG 1-98 is
expected to provide more information on the beneﬁts of
switching to letrozole after 2–3 years of tamoxifen, and
will clarify whether upfront or sequential AI use is the
optimal strategy. The ﬁnal results will be released in
2008 [51].
Extended adjuvant (including late extended adjuvant)
therapy
Many patients fear breast cancer recurrence [112] and
are reassured by the ‘‘safety net’’ of continuing medical
treatment and monitoring [9]. The MA.17 trial showed that
extended adjuvant therapy with letrozole gives patients the
opportunity of retaining the safety net for at least
5 more years after adjuvant tamoxifen [101], and these
results led to its approval in this indication. Currently,
letrozole is the only AI approved as an extended adjuvant
therapy.
The ﬁnal analysis of MA.17 after a median follow-up of
30 months showed letrozole signiﬁcantly improved DFS
(42% reduction in risk vs. placebo), distant DFS (40%
reduction in risk vs. placebo) and, in node-positive patients,
overall survival (39% reduction in risk vs. placebo) [101].
A recent cohort analysis of the MA.17 trial data suggested
that the longer patients are exposed to letrozole, the greater
the beneﬁt, at least out to 48 months [59]. In addition, an
extension to the MA.17 trial (MA.17 Re-randomization) is
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letrozole for a further 5 years [102].
When a planned interim analysis of MA.17 revealed a
signiﬁcant advantage for letrozole, the trial was unblinded
and patients on placebo were given the option to switch to
letrozole [90]. In this non-randomized comparison,
women from the placebo arm who elected to switch to
letrozole also experienced an improvement in outcome
when compared with those who elected to have no
treatment [102].
Table 1 Safety proﬁle of letrozole in comparison with placebo (A) and tamoxifen (B) reported in postmenopausal women with early breast
cancer
Placebo
Acute toxicities reported Total number (%), any grade
101
Letrozole (n = 2,572) Placebo (n = 2,577)
Edema 571 (22) 542 (21)
Hypertension 130 (5) 129 (5)
Hot ﬂushes 1,486 (58)
a 1383 (54)
Fatigue 999 (39) 998 (39)
Sweating 782 (30) 760 (29)
Anorexia 142 (6)
a 110 (4)
Constipation 363 (14) 382 (15)
Diarrhea 168 (7) 176 (7)
Nausea 308 (12) 314 (12)
Vaginal bleeding 145 (6) 196 (8)
a
Infection without neutropenia 124 (5) 112 (4)
Arthritis 167 (6) 137 (5)
Hypercholesterolemia 418 (16) 411 (16)
Dizziness 458 (18) 441 (17)
Insomnia 166 (6) 135 (5)
Depression 143 (6) 131 (5)
Headache 706 (27) 685 (27)
Arthralgia 651 (25)
a 532 (21)
Myalgia 380 (15)
a 310 (12)
Bone pain 141 (5) 149 (6)
Dyspnea 161 (6) 163 (6)
Alopecia 126 (5)
a 89 (3)
Vaginal dryness 147 (6) 129 (5)
Tamoxifen
Worst grade adverse events recorded within ﬁrst 28 days Total number (%), any grade
51
Letrozole (n = 3,975) Tamoxifen (n = 3,988)
CVA or TIA 39 (1.0) 41 (1.0)
Thromboembolic event 61 (1.5) 140 (3.5)
a
Cardiac event (IHD, CF) 162 (4.1) 153 (3.8)
Other CV event 19 (0.5)
a 8 (0.2)
Vaginal bleeding 132 (3.3) 263 (6.6)
Hot ﬂushes 1332 (33.5) 1516 (38.0)
a
Night sweats 554 (13.9) 647 (16.2)
a
Fracture 225 (5.7)
a 159 (4.0)
Arthralgia 806 (20.3)
a 491 (12.3)
Myalgia 254 (6.4) 243 (6.1)
CV cardiovascular, CVA cerebrovascular accident, TIA transient ischemic attack, IHD ischemic heart disease, CF cardiac failure
a Signiﬁcant difference
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adjuvant therapy, even in patients at low risk of recurrence.
One study shows that with systemic adjuvant therapy,
patients with node-negative breast cancer have a ‡25%
10-year risk of relapse and a corresponding 10-year breast
cancer death rate as high as ‡10%, depending on tumor
grade and size [113]. Thus, the proven efﬁcacy of letrozole
given after a tamoxifen-free period means that physicians
need to discuss the option of restarting endocrine therapy
with almost all patients. Physicians have to consider
how best to address this topic with patients who are up to
2–3 years out beyond their initial 5 years of tamoxifen, i.e.
about 5–8 years after their initial diagnosis. This will be a
major communication challenge and create a dilemma for
patients who may feel well and have put their breast cancer
behind them.
Safety and compliance issues
The clinical beneﬁts of AIs and tamoxifen are generally
achieved without a major detrimental effect on overall
QOL [114]. Data from the MA.17 trial, which is the only
large adjuvant trial comparing AI therapy not with
tamoxifen but with placebo, showed that overall QOL was
maintained during extended therapy with letrozole, and
only a minority of patients experienced substantial changes
in QOL, which were compatible with a reduction in
estrogen synthesis [115]. It is important to recognize that
patients may attribute such changes to their treatment,
whereas they could in fact be symptoms of menopause
[116]. However, side effects do occur, which not only
affect patient adherence to endocrine therapy [117] but can
also lead to additional morbidity and even serious or life-
threatening complications in a small minority of patients
[51, 52, 90, 99, 108, 109].
The main safety concerns with long-term estrogen
deprivation include potential effects on bone health, car-
diac health, lipid proﬁle, cognitive functioning, and sexual
health [100]. The MA.17 trial showed that letrozole is well-
tolerated in comparison with placebo [101], and BIG 1-98
showed that letrozole was better tolerated than tamoxifen
[51] (Table 1). A recent patient-reported outcomes study in
104 tamoxifen-intolerant women found that switching to
letrozole was associated with a signiﬁcant reduction in hot
ﬂushes (P = 0.001) and signiﬁcant improvements in QOL
(P = 0.001) and mood (P = 0.04). Furthermore, when
given the choice of continuing therapy, 66% of women
indicated that they preferred to remain on letrozole, while
only 24% preferred to go back to tamoxifen [118].
Despite an increase in newly diagnosed osteoporosis
with AIs, no signiﬁcant difference in clinical fracture rate
was seen between letrozole and placebo [101]. A
companion study to MA.17 showed that there was only a
modest increase in bone resorption and reduction in bone
mineral density (BMD) in the spine and hip with letrozole
compared with placebo [119]. Consequently, patients
should be made aware of the risk of osteoporosis and given
advice on lifestyle measures (e.g. exercise, diet, vitamins)
to reduce risk. A baseline BMD measurement should be
obtained for all patients before starting therapy with an AI.
BMD should then be measured annually, and patients at
high risk of osteoporosis should be considered for pro-
phylactic use of a bisphosphonate [120, 121]. However,
recent data from ATAC may be reassuring for patients
facing upfront AI therapy, since they indicate that women
with normal initial BMD did not develop osteoporosis
during a 5-year AI treatment [122].
Letrozole has been associated with an increase in
arthralgia compared with placebo or tamoxifen, and
myalgia compared with placebo [51, 101]. Arthralgia and
joint pain can be bothersome and may lead to impaired
mobility. Patients need to be advised that constant exer-
cising of the joints will alleviate this adverse event and that
use of nonsteroidal anti-inﬂammatory drugs over a certain
period of time may be helpful. Moreover, these complaints
seem to be most frequent in the beginning of AI therapy
[123].
Another potential consequence of endocrine therapy is a
detrimental effect on sexual health [115, 116]. Vaginal
dryness is a consequence of menopause and treatments that
cause menopausal symptoms, and has an important bearing
on sexual health and well-being of breast cancer survivors
[124]. Vaginal dryness can be a signiﬁcant problem that
can interfere with the stability of relationships [125], and
patients need to receive counseling with regard to this issue
[126]. It has been shown that clinical assessment and an
active intervention program for menopausal symptom
management in breast cancer survivors can lead to an
improvement in sexual functioning [127]. A recent report
demonstrated that the use of local estradiol therapy may
cause elevation of serum estradiol and may therefore be
contraindicated in postmenopausal women on AI therapy
[128]. So far, such data do not exist for estradiol-containing
compounds; thus, local estradiol treatment may be indi-
cated in individual cases. Androgen treatment may also
improve sexual well-being in postmenopausal women
[129], yet the oncological safety of this approach has not
been validated in patients receiving AI therapy. Of note,
the incidence of vaginal dryness in the MA.17 trial was
similar in the letrozole and placebo groups (Table 1)[ 101].
Differential effects on lipid proﬁles and cardiac risk
have been reported between tamoxifen and AIs [51, 130,
131], but data from the Letrozole, Exemestane, and
Anastrozole Pharmacodynamics trial, directly comparing
the effects of anastrozole, letrozole, and exemestane on
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123lipid proﬁles in healthy postmenopausal women, suggest
that the steroidal and nonsteroidal inhibitors have a sim-
ilar impact on lipid proﬁles [132]. On the basis of
evidence from large randomized trials, when comparing
letrozole with tamoxifen or placebo, it appears that le-
trozole does not have clinically relevant adverse effects
on lipids or cardiac risk during long-term adjuvant ther-
apy, although further assessment is warranted [51, 101,
133].
While letrozole is well-tolerated, and any side effects
that do occur can be managed, it is essential that patients
are motivated to stay on therapy. This can be a particular
challenge in the extended adjuvant setting. Thus, as
patients now face the prospect of receiving endocrine
therapy for 10 years or more, it is important to consider the
overall life-long beneﬁts and risks from the individual’s
perspective. A low burden of adverse events and mainte-
nance of QOL is important in maintaining adherence to
long-term treatment [60]. In the MA.17 trial, the rate of
patients choosing to discontinue therapy during the ﬁrst
year was similar for letrozole (n = 256/2,575) and placebo
(n = 254/2,582) [90]. Letrozole is ingested orally and can
be safely and conveniently taken at home. Physician con-
tact with oral endocrine therapy can be much less frequent
than, for example, with orally active chemotherapy where
regular blood tests, side-effect monitoring, and resulting
dose modiﬁcations make frequent physician contact man-
datory. Patients with breast cancer prefer oral cancer
therapy providing that it does not compromise treatment
efﬁcacy [134].
Conclusions
Patients with breast cancer face bewildering choices at a
time when they are experiencing highly stressful cir-
cumstances. Moreover, many of these women are not
well-informed and thus are not able to take part in
treatment decisions. The Gathering Information on
Adjuvant Endocrine therapy initiative decided to delin-
eate women’s knowledge and experience of adjuvant
endocrine therapy. Results thus far indicate that only
22% of patients were fully or highly involved in the
decision to start adjuvant endocrine therapy [135, 136].
Many of the women who took part in the survey were
not satisﬁed with the degree to which they were involved
in treatment decision-making, and women 60 years or
older had the lowest levels of involvement [135, 136].
The results from this survey show that information pro-
vided to patients about adjuvant endocrine therapy is
suboptimal and indicate the need for programs to raise
patient awareness. The medical community has a
responsibility to help patients understand their prospects
for survival and make the right choices about treatment
[24]. Doctor–patient discussions and programs to raise
patient awareness will increase patients’ knowledge about
the individualization of treatment and may increase the
number of women who take an active role in treatment
decisions.
Patients with hormone-responsive breast cancer should be
offered the opportunity of receiving the most effective
endocrine therapy. Clinical evidence suggests that post-
menopausal women should receive an AI rather than
tamoxifen as their ﬁrst option if tumor characteristics and
individual side-effect proﬁles support this choice. Letrozole
has consistently demonstrated superiority over tamoxifen in
the metastatic and adjuvant treatment settings [51, 74, 91,
101]. As a result of its innovative clinical trial program [51,
74, 101], letrozole is approved for use in postmenopausal
women throughout the breast cancer care continuum [137].
From the patient’s perspective, the major beneﬁts of le-
trozole are improving prospects for long-term survivorship
(‘‘cure’’) in the adjuvant setting and delaying progression
and the need for chemotherapy in the metastatic setting.
Endocrine therapy is very effective, has a generally
favorable safety proﬁle, and adds to the efﬁcacy of
chemotherapy. However, a major challenge for both
physicians and patients is ensuring compliance with long-
term daily therapy. This may be a particular problem in
the extended adjuvant setting, where the patient may face
the prospect of life-long therapy. As patients no longer
feel sick, it is understandable that they may forget to take
a dose and gradually lose interest in continuing with the
treatment. Letrozole is well-tolerated and, as with all AIs,
the majority of adverse events are secondary to the sup-
pression of estrogen. The most important adverse events
from the patient’s perspective are the ‘‘visible’’ ones, such
as hot ﬂushes, vaginal dryness, and arthralgias. To
achieve optimal compliance, patients need to feel that
physicians are taking their adverse events seriously and
taking appropriate steps to alleviate any problems. Phy-
sicians who treat very few breast cancer patients may not
have sufﬁcient experience with AIs to satisfactorily
manage individuals who are experiencing these adverse
events.
Letrozole is likely to continue to play a major role in the
management of breast cancer in all settings (see the paper
in this supplement by Drs. Ellis and Ma, on Femara
1 and
the future). Considering its efﬁcacy and favorable side-
effect proﬁle, it is the logical choice for inclusion in new
regimens, including combinations with novel agents. As
the future unfolds, the management of breast cancer is set
for further change, and it is essential that patients are
informed and educated so that they can actively participate
in treatment decisions and thus derive the most beneﬁt
from treatment advances.
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